GERON Business Summary

Geron Corporation (GERN) is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of RYTELO (imetelstat), a first-in-class telomerase inhibitor. Following its 2024 FDA approval and subsequent EU authorization, RYTELO is indicated for adult patients with transfusion-dependent anemia due to lower-risk myelodysplastic syndromes (LR-MDS). The company operates within a single oncology segment, focusing on the commercialization of RYTELO and the clinical advancement of its Phase 3 IMpactMF trial for relapsed/refractory myelofibrosis. For fiscal year 2026, Geron has projected net product revenue between $220 million and $240 million, driven by targeted healthcare provider engagement and international market expansion. In the competitive landscape, Geron contends with Bristol Myers Squibb (Reblozyl), Incyte (Jakafi), and Merck (Bomedemstat), positioning itself as a differentiated, disease-modifying alternative to traditional erythroid-stimulating agents and JAK inhibitors. Originally founded in 1992 by Michael West and Alex Barkas, Geron is currently led by President and CEO Harout Semerjian, who took the helm in August 2025 bringing over 30 years of oncology experience from leadership roles at Novartis, Ipsen, and GlycoMimetics. The executive team includes EVP and CFO Michelle Robertson, formerly of Editas Medicine and Momenta Pharmaceuticals; EVP and Chief Commercial Officer Ahmed ElNawawi, who previously scaled commercial operations at Stemline Therapeutics; and Senior VP and CTO Shanthakumar Tyavanagimatt, a veteran of global drug development. The company’s strategic direction is overseen by Board Chair Elizabeth G. O’Farrell, with significant institutional backing from notable investors including RA Capital Management, RTW Investments, BlackRock, and Vanguard Group.